STOCK TITAN

Relay Therapeutics Inc - RLAY STOCK NEWS

Welcome to our dedicated news page for Relay Therapeutics (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Relay Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Relay Therapeutics's position in the market.

Rhea-AI Summary
Relay Therapeutics, Inc. (RLAY) will participate in three upcoming fireside chats at major healthcare conferences in March 2024. The company aims to showcase its innovative approach to drug discovery using computational and experimental technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
conferences
-
Rhea-AI Summary
Relay Therapeutics, Inc. (RLAY) reported fourth quarter and full year 2023 financial results, highlighting progress in clinical programs like RLY-2608 and RLY-5836. The company announced approximately $750 million in cash, cash equivalents, and investments at the end of Q4 2023, expected to fund operations into the second half of 2026. Key milestones for 2024 include updates on RLY-2608 and lirafugratinib, and the disclosure of new pre-clinical programs. Despite positive advancements, the company experienced an increase in net loss, R&D expenses, and G&A expenses compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
earnings
-
Rhea-AI Summary
Relay Therapeutics, Inc. (RLAY) to report Q4 and full year 2023 financial results and corporate highlights on February 22, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
earnings
Rhea-AI Summary
Relay Therapeutics, Inc. (Nasdaq: RLAY) will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:30 a.m. ET. The presentation will be webcast live and may be accessed through Relay Therapeutics’ website. An archived replay of the webcast will be available for up to 30 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
conferences
-
Rhea-AI Summary
Relay Therapeutics, Inc. (Nasdaq: RLAY) has entered into a securities purchase agreement for a private placement financing with Nextech to sell 2.5 million shares of common stock at a price per share of $12.00, expected to result in gross proceeds of $30.0 million. The company plans to use the net proceeds to advance RLY-2608 towards registrational trial(s), advance its preclinical pipeline, and for working capital and other general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
none
-
Rhea-AI Summary
Relay Therapeutics, Inc. (Nasdaq: RLAY) announced that Sanjiv Patel, M.D., President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will be webcast live and may be accessed through Relay Therapeutics’ website. An archived replay of the webcast will be available for up to 30 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.66%
Tags
conferences
Rhea-AI Summary
Relay Therapeutics, Inc. (Nasdaq: RLAY) to participate in fireside chat at Stifel 2023 Healthcare Conference. Webcast available on company website. Archived replay accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
conferences
-
Rhea-AI Summary
Relay Therapeutics reported initial data on RLY-4008 showing durable responses in FGFR2-altered solid tumors. They also announced plans to initiate RLY-2608 triplet combinations in HR+/HER2- breast cancer. The company updated its pipeline to extend cash runway by approximately 1 year. They have $811 million in cash at the end of Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
earnings
-
Rhea-AI Summary
Relay Therapeutics to report Q3 2023 financial results on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
earnings
Rhea-AI Summary
Relay Therapeutics announces initial clinical data for RLY-4008 in patients with FGFR2-altered solid tumors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
Relay Therapeutics Inc

Nasdaq:RLAY

RLAY Rankings

RLAY Stock Data

1.07B
93.01M
3.49%
99.08%
8.38%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About RLAY

relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate